JP2009515901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515901A5 JP2009515901A5 JP2008540275A JP2008540275A JP2009515901A5 JP 2009515901 A5 JP2009515901 A5 JP 2009515901A5 JP 2008540275 A JP2008540275 A JP 2008540275A JP 2008540275 A JP2008540275 A JP 2008540275A JP 2009515901 A5 JP2009515901 A5 JP 2009515901A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- treatment
- inhibitor
- patient
- inhibitor according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73676305P | 2005-11-14 | 2005-11-14 | |
| US60/736,763 | 2005-11-14 | ||
| PCT/US2006/044146 WO2007059106A2 (en) | 2005-11-14 | 2006-11-14 | Administration of mntor inhibitor to treat patients with cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191029A Division JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515901A JP2009515901A (ja) | 2009-04-16 |
| JP2009515901A5 true JP2009515901A5 (https=) | 2010-01-21 |
| JP5709354B2 JP5709354B2 (ja) | 2015-04-30 |
Family
ID=38049229
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540275A Expired - Fee Related JP5709354B2 (ja) | 2005-11-14 | 2006-11-14 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
| JP2013191029A Pending JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191029A Pending JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070185150A1 (https=) |
| EP (2) | EP2662082A1 (https=) |
| JP (2) | JP5709354B2 (https=) |
| CN (2) | CN102579467A (https=) |
| AU (1) | AU2006315512B2 (https=) |
| CA (1) | CA2629714A1 (https=) |
| EA (1) | EA015922B1 (https=) |
| IL (1) | IL191356A0 (https=) |
| WO (1) | WO2007059106A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100266590A1 (en) * | 2006-08-02 | 2010-10-21 | Demetri George D | Combination therapy |
| JP2010509400A (ja) * | 2006-11-14 | 2010-03-25 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 経口処方組成物 |
| CA2719134C (en) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| ES2645692T3 (es) | 2008-11-11 | 2017-12-07 | The Board Of Regents,The University Of Texas System | Microcápsulas de rapamicina y su uso para el tratamiento del cáncer |
| WO2010120599A2 (en) | 2009-04-16 | 2010-10-21 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| US8911766B2 (en) * | 2009-06-26 | 2014-12-16 | Abbott Cardiovascular Systems Inc. | Drug delivery compositions including nanoshells for triggered drug release |
| WO2011024168A2 (en) * | 2009-08-26 | 2011-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| EP2558092B1 (en) * | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
| JP2012061053A (ja) | 2010-09-14 | 2012-03-29 | Yuuki Kitaoka | 投薬装置、投薬装置の作動方法及び投薬方法 |
| AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| BR112013027486A2 (pt) * | 2011-04-25 | 2017-02-14 | Novartis Ag | combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor |
| KR102040997B1 (ko) * | 2011-12-02 | 2019-11-27 | 시그날 파마소티칼 엘엘씨 | 7-(6-(2-히드록시프로판-2-일)피리딘-3-일)-1-((트랜스)-4-메톡시시클로헥실)-3,4-디히드로피라지노[2,3-b]피라진-2(1H)-온, 그의 고체 형태의 제약 조성물 및 그의 사용 방법 |
| WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| US9757432B2 (en) * | 2012-11-14 | 2017-09-12 | Ohio State Innovation Foundation | Materials and methods useful for treating glioblastorna |
| WO2014160328A1 (en) | 2013-03-13 | 2014-10-02 | The Board Of Regents Of The University Of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| EP3089737B1 (en) | 2013-12-31 | 2021-11-03 | Rapamycin Holdings, LLC | Oral rapamycin nanoparticle preparations and use |
| CN106166296A (zh) * | 2016-07-01 | 2016-11-30 | 江南大学 | 一种辅助雷帕霉素治疗多种肿瘤的药物组合物 |
| CN107714719A (zh) * | 2017-11-08 | 2018-02-23 | 上海市第妇婴保健院 | 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用 |
| JP7530116B2 (ja) * | 2020-02-21 | 2024-08-07 | コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー | エムトール信号伝達抑制剤を有効成分として含む癌の予防又は治療用薬剤学的組成物 |
| CN114767867A (zh) * | 2021-12-22 | 2022-07-22 | 中山大学孙逸仙纪念医院 | 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| DK0525960T3 (da) | 1991-06-18 | 1996-04-15 | American Home Prod | Anvendelse af rapamycin til behandling af T-celle leukæmi/lymfon |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| ES2295093T3 (es) | 1993-04-23 | 2008-04-16 | Wyeth | Conjugados y anticuerpos de rapamicina. |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| ATE398448T1 (de) | 1993-09-28 | 2008-07-15 | Scherer Gmbh R P | Herstellung von weichgelatinekapseln |
| US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0000482D0 (en) | 2000-01-11 | 2000-03-01 | Norton Healthcare Ltd | Enteric coated pharmaceutical formulation |
| MX368013B (es) | 2001-02-19 | 2019-09-13 | Novartis Ag | Tratamiento de cáncer. |
| EA010184B1 (ru) * | 2001-04-06 | 2008-06-30 | Уайт | Применение противоопухолевых комбинаций рапамицина с гемцитабином или 5-фторурацилом |
| WO2002096933A1 (en) | 2001-05-30 | 2002-12-05 | Novartis Ag | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives |
| PT1478648E (pt) | 2002-02-01 | 2014-07-15 | Ariad Pharma Inc | Compostos contendo fósforo e suas utilizações |
| AU2003272489B2 (en) | 2002-09-17 | 2008-11-13 | Wyeth | Granulated formulation of the rapamycin ester CCI779 |
| CA2536140A1 (en) * | 2003-08-18 | 2005-02-24 | Pfizer Products Inc. | Dosing schedule for erbb2 anticancer agents |
| GB0327840D0 (en) * | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| EP1701698B1 (en) | 2004-01-08 | 2008-01-16 | Wyeth a Corporation of the State of Delaware | Directly compressible pharmaceutical composition for the oral admimistration of cci-779 |
| US7405497B2 (en) | 2004-04-13 | 2008-07-29 | Electrovaya Inc. | Integrated power supply system |
| US20080081053A1 (en) * | 2004-09-30 | 2008-04-03 | Bedrosian Camille L | Treatment Method |
| WO2006089312A2 (en) * | 2005-02-15 | 2006-08-24 | Wyeth | Orally bioavailable cci-779 tablet formulations |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| DE102005017313A1 (de) | 2005-04-14 | 2006-10-19 | Volkswagen Ag | Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug |
| US20070105887A1 (en) * | 2005-11-04 | 2007-05-10 | Wyeth | Antineoplastic combinations of temsirolimus and sunitinib malate |
-
2006
- 2006-11-14 WO PCT/US2006/044146 patent/WO2007059106A2/en not_active Ceased
- 2006-11-14 AU AU2006315512A patent/AU2006315512B2/en not_active Ceased
- 2006-11-14 CN CN2012100014166A patent/CN102579467A/zh active Pending
- 2006-11-14 EP EP13179744.1A patent/EP2662082A1/en not_active Withdrawn
- 2006-11-14 JP JP2008540275A patent/JP5709354B2/ja not_active Expired - Fee Related
- 2006-11-14 EP EP06844354A patent/EP1962839A4/en not_active Withdrawn
- 2006-11-14 EA EA200801309A patent/EA015922B1/ru not_active IP Right Cessation
- 2006-11-14 US US11/598,850 patent/US20070185150A1/en not_active Abandoned
- 2006-11-14 CA CA002629714A patent/CA2629714A1/en not_active Abandoned
- 2006-11-14 CN CN2006800510347A patent/CN101360495B/zh not_active Expired - Fee Related
-
2008
- 2008-05-12 IL IL191356A patent/IL191356A0/en unknown
-
2013
- 2013-09-13 JP JP2013191029A patent/JP2014012721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515901A5 (https=) | ||
| JP2009539769A5 (https=) | ||
| JP2014040437A5 (https=) | ||
| JP2008530248A5 (https=) | ||
| JP2009545601A5 (https=) | ||
| IL252715A0 (en) | Combinations and forms of administration of therapeutic agents and combined treatment | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2009506054A5 (https=) | ||
| JP2013518124A5 (https=) | ||
| JP2015527374A5 (https=) | ||
| JP2009536956A5 (https=) | ||
| JP2005530735A5 (https=) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| JP2008517991A5 (https=) | ||
| JP2011500589A5 (https=) | ||
| JP2015510945A5 (https=) | ||
| JP2011500650A5 (https=) | ||
| JP2014526558A5 (https=) | ||
| JP2007538066A5 (https=) | ||
| JP2010519274A5 (https=) | ||
| CN104146999A (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 | |
| CY1112814T1 (el) | Αντιμετωπιση ανθεκτικων στα φαρμακα ογκων | |
| HK1133829A (en) | Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer | |
| WO2009100656A8 (zh) | 2-亚甲基-5-取代亚甲基环戊酮类衍生物及其应用 |